OG

Organigram Global Inc.

OGIHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$259.2M
+62.2% YoY
Net Income
-$24.8M
+45.5% YoY
EBITDA
$2.7M
+111.8% YoY
Free Cash Flow
$16.1M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 MACD Negative CrossoverHistogram -0.0027, negative momentum
Jul 1 MACD Positive CrossoverHistogram +0.0103, positive momentum
About Organigram Global Inc.

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. The company carries a $133.0M market cap, placing it firmly in the micro-cap category. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands.

Where OGI stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, OGI finished 35.51% below its 150-day moving average ($1.38) and 39.04% below its 200-day moving average ($1.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is OGI overbought or oversold?

At the July 15, 2026 close, OGI's RSI(14) was 39.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$133.0M
Fwd P/E42.95
EPS$-0.15
Beta1.85
52W Change-39.0%
ROE-5.9%
Analysis

Organigram Global Inc. carries $8.2M in total debt against $5.1M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $16.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -5.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $79.2M (2021) to $259.2M (2025), reflecting a 227% increase over the period.

With a beta above 1.5, OGI tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Organigram Global Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
OGI: Organigram Global Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance